Ulthera
Date | Investors | Amount | Round |
---|---|---|---|
$5.5m | Series A | ||
$22.5m | Series B | ||
N/A | $1.2m | Early VC | |
$10.5m | Series C | ||
$600m Valuation: $600m | Acquisition | ||
Total Funding | CAD54.1m |
Related Content
Recent News about Ulthera
EditUlthera, Inc. operates in the aesthetic medical device market, specializing in non-invasive skin lifting and tightening solutions. The company's flagship product, Ultherapy, utilizes ultrasound technology to stimulate collagen production, providing a non-surgical alternative for lifting the neck, chin, brow, and improving lines and wrinkles on the chest. Ulthera serves a diverse clientele, including dermatologists, plastic surgeons, and medical spas, targeting individuals seeking non-invasive cosmetic enhancements. The business model revolves around the sale of Ultherapy devices and consumables, as well as training and support services for medical professionals. Revenue is generated through direct sales, leasing options, and ongoing service agreements. Ulthera's market is characterized by a growing demand for non-surgical aesthetic treatments, driven by advancements in technology and increasing consumer preference for minimally invasive procedures.
Keywords: non-invasive, ultrasound therapy, skin lifting, collagen stimulation, aesthetic medical device, dermatologists, plastic surgeons, medical spas, cosmetic enhancements, FDA-cleared.